Effect of portal pressure gradient reduction on outcomes after transjugular intrahepatic portosystemic shunt in portal hypertension patients

doi:10.4254/wjh.v17.i3.103261

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (90)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-6) series.

Item

Count

PDF

HTML

Figures (1-6)

Tables (1-6)

Sum=75

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=3

Mar 27, 2025 (publication date) through Mar 29, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Mar 27, 2025; 17(3): 103261
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.103261

Effect of portal pressure gradient reduction on outcomes after transjugular intrahepatic portosystemic shunt in portal hypertension patients

Zhi-Bin Wang, Bing Zhu, Ming-Ming Meng, Yi-Fan Wu, Yu Zhang, Dong-Ze Li, Hua Tian, Fu-Chuan Wang, Yi-Fan Lv, Qiu-Xia Ye, Fu-Quan Liu

Zhi-Bin Wang, Ming-Ming Meng, Yi-Fan Wu, Yu Zhang, Yi-Fan Lv, Qiu-Xia Ye, Fu-Quan Liu, Center for Minimally Invasive Treatment of Liver Diseases, Beijing Shijitan Hospital, Capital Medical University, Beijing 100080, China

Bing Zhu, Dong-Ze Li, Hua Tian, Fu-Chuan Wang, Fu-Quan Liu, Center for Diagnosis and Treatment of Hepatic Vascular Diseases, The Fifth Medical Center of Chinese People’s Liberation Army General Hospital, Beijing 100071, China

Author contributions: Wang ZB, Zhu B, Meng MM, and Wu YF contributed to the study design and data collection; Zhang Y and Li DZ performed data analysis; Tian H, Wang FC, Lv YF, and Ye QX assisted with result interpretation; Liu FQ supervised the study and is the corresponding author; and all authors reviewed and approved the final manuscript.

Supported by the “14th Five-Year” Talent Training Program of Beijing Shijitan Hospital, Capital Medical University, No. 2023 LJRCLFQ.

Institutional review board statement: This retrospective cohort study received approval from the Institutional Review Boards of Beijing Shijitan Hospital, Capital Medical University, and the Fifth Medical Center of the Chinese People’s Liberation Army General Hospital (No. KY-2023-12-83-1).

Informed consent statement: Patients were not required to provide informed consent for this study because the analysis used anonymous clinical data that were obtained after patient had agreed to treatment with written consent.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Data sharing statement: sharing statement: The datasets generated and analyzed during the current study are not publicly available due to patient confidentiality and privacy concerns but are available from the corresponding author upon reasonable request and with permission from the Institutional Review Boards of Beijing Shijitan Hospital, Capital Medical University, and the Fifth Medical Center of the Chinese People’s Liberation Army General Hospital.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Fu-Quan Liu, MD, Professor, Center for Minimally Invasive Treatment of Liver Diseases, Beijing Shijitan Hospital, Capital Medical University, No. 10 Tieyi Road, Yangfangdian, Haidian district, Beijing 100080, China. lfuquan@aliyun.com

Received: November 14, 2024
Revised: February 1, 2025
Accepted: March 4, 2025
Published online: March 27, 2025
Processing time: 132 Days and 18 Hours

Core Tip

Core Tip: This study evaluates the impact of portal pressure gradient (PPG) reduction following transjugular intrahepatic portosystemic shunt (TIPS) on clinical outcomes in portal hypertension patients. Findings reveal that a significant PPG reduction (> 50%) post-TIPS is linked to decreased risks of rebleeding, shunt dysfunction, hepatocellular carcinoma, and mortality. However, it also raises the risk of hepatic encephalopathy and liver failure. Additionally, portal vein diameter influences the degree of PPG reduction. These insights highlight the need for personalized management strategies to optimize TIPS outcomes, balancing benefits and potential risks for improved patient prognosis.